Medical Pharmacology: Chapter 15: Local Anesthetics -- Module 2: Clinical Pharmacology of Individual Agents, Adjuvants, Toxicology, and Drug Interactions

Chapter 15: Local Anesthetics — Module 2: Clinical Pharmacology of Individual Agents, Adjuvants, Toxicology, and Drug Interactions
Tier: Core Concepts — Foundational Knowledge (22 questions)

1. A second-year medical student is reviewing local anesthetic classifications and wants to understand the metabolic fate of lidocaine (a widely used injectable and topical local anesthetic). Which of the following correctly identifies lidocaine's chemical class and its primary route of elimination?

A) Lidocaine is an ester-class local anesthetic that is rapidly hydrolyzed by plasma pseudocholinesterase (butyrylcholinesterase, the plasma enzyme that also metabolizes succinylcholine).
B) Lidocaine is an amide-class local anesthetic that undergoes renal elimination as unchanged drug without significant hepatic metabolism.
C) Lidocaine is an amide-class local anesthetic that is metabolized primarily by hepatic cytochrome P450 enzymes, principally CYP3A4 and CYP1A2.
D) Lidocaine is an ester-class local anesthetic that undergoes hepatic glucuronidation before renal excretion.
E) Lidocaine is an amide-class local anesthetic that is metabolized primarily by plasma pseudocholinesterase, the same enzyme responsible for succinylcholine hydrolysis.

ANSWER: C

Rationale:

Option C is correct. Lidocaine belongs to the amide class of local anesthetics — identified by an amide linkage (-NHCO-) between the aromatic ring and the intermediate chain — and is metabolized primarily in the liver by cytochrome P450 enzymes, principally CYP3A4 and CYP1A2. This hepatic dependence means that patients with significant liver disease or reduced hepatic blood flow (such as those in heart failure or shock) will have impaired lidocaine clearance and are at increased risk of systemic accumulation and toxicity with repeated or continuous dosing.

Option A: Option A is incorrect because lidocaine is not an ester; ester-class agents (such as procaine, chloroprocaine, and tetracaine) are the ones hydrolyzed by plasma pseudocholinesterase.
Option B: Option B is incorrect because lidocaine does not undergo significant renal elimination as unchanged drug; hepatic metabolism is the primary pathway, and the distinction between amide (hepatic) and ester (plasma) metabolism is a foundational classification concept.
Option D: Option D is incorrect because lidocaine is not an ester and does not undergo glucuronidation as its primary metabolic route.
Option E: Option E is incorrect because plasma pseudocholinesterase metabolizes ester agents, not amide agents; this is one of the most clinically important distinctions in local anesthetic pharmacology and underlies the relevance of pseudocholinesterase deficiency testing before using ester-class agents.

2. Which of the following local anesthetics has the shortest plasma half-life and achieves this extremely rapid elimination through hydrolysis by plasma pseudocholinesterase (butyrylcholinesterase)?

A) Chloroprocaine, an ester-class local anesthetic with a plasma half-life of under 60 seconds in patients with normal pseudocholinesterase activity.
B) Lidocaine, an amide-class local anesthetic whose rapid hepatic metabolism produces a plasma half-life of approximately 10–15 minutes.
C) Ropivacaine, a long-acting amide whose pure S(−)-enantiomer configuration accelerates enzymatic breakdown compared to racemic bupivacaine.
D) Mepivacaine, an amide-class local anesthetic that undergoes unusually rapid renal clearance due to its low protein binding.
E) Tetracaine, an ester-class local anesthetic that is hydrolyzed so rapidly by pseudocholinesterase that it is used exclusively for short-duration procedures.

ANSWER: A

Rationale:

Option A is correct. Chloroprocaine is an ester-class local anesthetic whose plasma half-life in patients with normal pseudocholinesterase activity is under 60 seconds — making it the most rapidly eliminated local anesthetic in clinical use. This near-instantaneous hydrolysis is the pharmacokinetic property that makes chloroprocaine exceptionally safe from a systemic toxicity standpoint: absorbed drug is destroyed in the plasma before it can accumulate to toxic concentrations. This safety profile makes chloroprocaine the preferred agent for urgent epidural conversion in obstetrics (for example, when a labor epidural must be rapidly extended to provide surgical anesthesia for an emergency cesarean delivery).

Option B: Option B is incorrect; lidocaine is an amide metabolized hepatically with a plasma half-life of approximately 1.5–2 hours, not 10–15 minutes.
Option C: Option C is incorrect; ropivacaine's S(−)-enantiomer configuration reduces its cardiac channel binding affinity compared to racemic bupivacaine, but it does not accelerate enzymatic breakdown — ropivacaine is an amide metabolized by hepatic CYP3A4 and CYP1A2, not by pseudocholinesterase.
Option D: Option D is incorrect; mepivacaine is an amide with hepatic metabolism and does not undergo unusually rapid renal clearance.
Option E: Option E is incorrect; tetracaine is an ester hydrolyzed by pseudocholinesterase, but its hydrolysis rate is substantially slower than chloroprocaine, and it is used for spinal anesthesia and topical ophthalmic anesthesia — not for rapid short-duration procedures based on speed of elimination.

3. A local anesthetic with a pKa (the pH at which 50% of the drug exists in the ionized form and 50% in the unionized free-base form) closer to physiologic pH will have a faster clinical onset than one with a higher pKa. Which of the following best explains why this is true?

A) A lower pKa increases the total dose of local anesthetic that can be safely administered, allowing more drug to reach the nerve before toxic concentrations are reached.
B) A lower pKa increases the water solubility of the local anesthetic, allowing faster diffusion through the aqueous extracellular space to reach the nerve membrane.
C) A lower pKa increases the ionized fraction of the drug at physiologic pH, and the ionized form is the membrane-permeable species that crosses the nerve sheath to reach sodium channels.
D) A lower pKa reduces protein binding, which frees more drug from plasma proteins and increases the concentration available to diffuse to the nerve.
E) A lower pKa means a greater fraction of the drug exists in the unionized free-base form at physiologic pH (7.4), and it is this lipid-soluble free-base form that crosses nerve sheaths and cell membranes to reach the sodium channel binding site.

ANSWER: E

Rationale:

Option E is correct. Local anesthetics are weak bases, and the fraction existing in the unionized (free-base) form at any given pH is determined by the Henderson-Hasselbalch relationship. At physiologic pH of 7.4, a drug with a pKa of 7.7 (such as mepivacaine) will have a larger unionized fraction than one with a pKa of 8.1 (such as bupivacaine). The unionized free-base form is lipid-soluble and membrane-permeable — it is the species that crosses the nerve sheath, the axonal membrane, and the myelin to reach the sodium channel. Once inside the axoplasm, the drug re-ionizes in the intracellular environment, and it is the ionized form that binds within the sodium channel pore to block conduction. The onset advantage of a lower pKa is therefore entirely attributable to a larger membrane-permeable free-base fraction, not to any direct effect on dose, water solubility, or protein binding. Option C has the pharmacology inverted — the ionized form is NOT membrane-permeable; it is the unionized free-base form that crosses membranes, while the ionized form binds inside the channel once the drug has entered the axon.

Option A: Option A is incorrect; pKa has no direct relationship to the maximum safe dose, which is determined by systemic toxicity thresholds.
Option B: Option B is incorrect; the free-base form is the lipid-soluble species, not a water-soluble one; it is the ionized form that is more water-soluble.
Option D: Option D is incorrect; pKa and protein binding are independent physicochemical properties, and a lower pKa does not reduce protein binding.

4. Bupivacaine is associated with a greater risk of fatal cardiac toxicity than lidocaine at equivalent plasma concentrations. Which of the following best explains the pharmacologic basis for bupivacaine's pronounced cardiac danger?

A) Bupivacaine has a lower pKa than lidocaine, allowing a larger unionized fraction to penetrate cardiac myocytes and reach intracellular calcium stores, triggering dysrhythmia through calcium overload.
B) Bupivacaine dissociates from cardiac sodium channels (Nav1.5) very slowly during diastole, so channels do not recover between beats — producing cumulative conduction block, QRS widening, and ventricular dysrhythmia that is highly refractory to standard resuscitation.
C) Bupivacaine irreversibly alkylates cardiac sodium channels, permanently blocking conduction in a dose-dependent fashion that cannot be reversed even with high-dose epinephrine.
D) Bupivacaine is a racemic mixture that preferentially blocks cardiac potassium channels (hERG), prolonging the QT interval and triggering torsades de pointes rather than ventricular fibrillation.
E) Bupivacaine undergoes active accumulation in cardiac mitochondria, where it uncouples oxidative phosphorylation and produces energy depletion — the primary mechanism of cardiovascular collapse.

ANSWER: B

Rationale:

Option B is correct. The cardiac toxicity of bupivacaine is explained by its unusually slow dissociation kinetics from the Nav1.5 cardiac sodium channel. All local anesthetics block sodium channels during the action potential (the "fast-in" phase), but they differ critically in how quickly they dissociate during the resting phase between beats (diastole — "slow-out"). Lidocaine dissociates rapidly enough during diastole that channels recover before the next beat; bupivacaine dissociates so slowly that channels remain blocked even at normal heart rates, producing progressive accumulation of block with each successive beat — a property described as "fast-in, slow-out" kinetics. The result is QRS complex (QRS) widening, ventricular dysrhythmia including ventricular fibrillation, and cardiovascular collapse that is notoriously resistant to epinephrine and defibrillation because the drug remains tightly bound in the channel. This mechanism is why lipid emulsion therapy (which acts as a lipid sink to extract bupivacaine from cardiac tissue) is the definitive treatment for bupivacaine-induced cardiac arrest. Option D is partially misleading; while bupivacaine is a racemic mixture, the primary cardiac mechanism is sodium channel blockade producing QRS widening and ventricular fibrillation, not QT prolongation and torsades.

Option A: Option A is incorrect; while bupivacaine's high lipid solubility does facilitate membrane penetration, the mechanism of cardiac toxicity is sodium channel kinetics, not calcium overload.
Option C: Option C is incorrect; bupivacaine binding to sodium channels is reversible, not covalent or irreversible — the danger is the slow reversal rate, not permanent blockade.
Option E: Option E is incorrect; mitochondrial uncoupling is not the primary mechanism of bupivacaine cardiac toxicity.

5. Epinephrine is frequently added to local anesthetic solutions before peripheral nerve block injection. What is the primary pharmacologic mechanism by which epinephrine prolongs the duration of the nerve block?

A) Epinephrine activates β₂-adrenergic receptors on Schwann cells (the myelin-forming cells surrounding peripheral nerves), stabilizing the myelin sheath and slowing the rate at which the local anesthetic diffuses away from the nerve.
B) Epinephrine directly blocks voltage-gated sodium channels in the nerve axon, adding its own conduction-blocking activity to that of the local anesthetic and producing a synergistic extension of the block.
C) Epinephrine alkalinizes the local tissue pH at the injection site by stimulating bicarbonate secretion from local cells, shifting the local anesthetic equilibrium toward the free-base form and prolonging sodium channel occupancy.
D) Epinephrine produces α₁-adrenergic receptor–mediated vasoconstriction at the injection site, reducing local blood flow and slowing the systemic absorption of the local anesthetic — keeping the drug in contact with the nerve for a longer time.
E) Epinephrine inhibits the activity of plasma pseudocholinesterase at the injection site, preventing local hydrolysis of ester-class agents and thereby extending their effective duration.

ANSWER: D

Rationale:

Option D is correct. Epinephrine's primary mechanism for prolonging nerve block duration is vasoconstriction mediated through α₁-adrenergic receptors on local blood vessels. By reducing blood flow to the injection site, epinephrine slows the rate at which the local anesthetic is absorbed into the systemic circulation, keeping higher drug concentrations at the nerve for a longer time. The magnitude of this effect varies by agent: for lidocaine (which is intrinsically vasodilatory), epinephrine can extend peripheral nerve block duration by 50–100%; for bupivacaine and ropivacaine (which have high lipid solubility and protein binding that already sustain neural binding), the proportional extension is smaller, approximately 15–30%. A secondary mechanism, particularly relevant in the neuraxial setting, is direct antinociceptive activity at spinal α₂-adrenergic receptors.

Option A: Option A is incorrect; epinephrine does not act on Schwann cells to stabilize myelin, and this is not a mechanism of block prolongation.
Option B: Option B is incorrect; epinephrine does not directly block sodium channels — it is a catecholamine that acts on adrenergic receptors, not a sodium channel blocker.
Option C: Option C is incorrect; epinephrine does not stimulate bicarbonate secretion, and pH alkalinization is achieved by deliberate addition of sodium bicarbonate as a separate adjuvant, not via epinephrine.
Option E: Option E is incorrect; epinephrine does not inhibit pseudocholinesterase, and this would not be relevant for amide agents regardless.

6. A patient develops cyanosis that does not improve with supplemental oxygen after a procedure involving prilocaine. A co-oximetry (multiwavelength oximetry) blood test confirms methemoglobin elevation. Which of the following correctly identifies the mechanism by which prilocaine produces this complication?

A) Prilocaine directly inhibits erythrocyte (red blood cell) carbonic anhydrase, impairing CO₂ transport and causing a chemical hypoxia that mimics methemoglobinemia on pulse oximetry.
B) Prilocaine's ester-class structure allows it to be hydrolyzed within red blood cells, releasing aromatic amine metabolites that competitively displace oxygen from hemoglobin without changing the iron oxidation state.
C) Prilocaine is metabolized in the liver to o-toluidine, an aromatic amine that oxidizes the iron in hemoglobin from the ferrous state (Fe²⁺, which binds oxygen) to the ferric state (Fe³⁺), producing methemoglobin — a form of hemoglobin incapable of carrying oxygen.
D) Prilocaine accumulates in red blood cells and directly cross-links hemoglobin subunits, shifting the oxygen-hemoglobin dissociation curve so far to the left that tissues cannot unload oxygen despite normal hemoglobin saturation.
E) Prilocaine inhibits the enzyme methemoglobin reductase within red blood cells, preventing the normal physiologic reduction of methemoglobin back to functional hemoglobin and allowing even trace methemoglobin production to accumulate to toxic levels.

ANSWER: C

Rationale:

Option C is correct. Prilocaine undergoes hepatic metabolism to o-toluidine, an aromatic amine metabolite that is the direct cause of methemoglobinemia. O-toluidine oxidizes the iron in hemoglobin from the ferrous (Fe²⁺) state — which is required for reversible oxygen binding — to the ferric (Fe³⁺) state, producing methemoglobin. Methemoglobin cannot bind or transport oxygen, and it also shifts the oxygen-hemoglobin dissociation curve leftward, impairing oxygen delivery to tissues. The clinical hallmark is cyanosis that fails to respond to supplemental oxygen (because the problem is not inadequate oxygen in the blood but inability to carry it) and a characteristic chocolate-brown blood color. The definitive treatment is methylene blue, which reduces Fe³⁺ back to Fe²⁺. This toxicity is dose-dependent and is rarely clinically significant below approximately 600 mg in healthy adults, but the threshold is substantially lower in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, neonates, and patients with pre-existing hypoxemia.

Option A: Option A is incorrect; prilocaine does not inhibit carbonic anhydrase, and this is not a mechanism of methemoglobinemia.
Option B: Option B is incorrect; prilocaine is an amide-class agent, not an ester, and red cell hydrolysis is not its metabolic pathway.
Option D: Option D is incorrect; hemoglobin cross-linking is not a mechanism of prilocaine toxicity.
Option E: Option E is incorrect; while methemoglobin reductase deficiency can predispose to methemoglobinemia, prilocaine does not inhibit this enzyme — its toxicity is mediated by the o-toluidine metabolite directly oxidizing iron.

7. Among all clinically used local anesthetics, cocaine occupies a unique pharmacologic position because it produces vasoconstriction through a mechanism not shared by any other agent in the class. What is this mechanism?

A) Cocaine inhibits the presynaptic reuptake transporter for norepinephrine (noradrenaline) at sympathetic nerve terminals, causing norepinephrine to accumulate in the synaptic cleft and producing sustained α-adrenergic–mediated vasoconstriction at the site of application.
B) Cocaine directly activates α₁-adrenergic receptors on vascular smooth muscle, mimicking the effect of endogenous norepinephrine and producing vasoconstriction independent of any effect on neurotransmitter reuptake.
C) Cocaine is an ester-class local anesthetic with unusually high lipid solubility that allows it to penetrate vascular smooth muscle cells and directly inhibit voltage-gated calcium channels, reducing calcium-mediated vasoconstriction tone while simultaneously blocking sodium channels in sensory nerves.
D) Cocaine releases stored norepinephrine from sympathetic varicosities (nerve terminals that store and release neurotransmitter) by reversing the direction of the norepinephrine transporter, similar to the mechanism of amphetamine.
E) Cocaine produces vasoconstriction by inhibiting acetylcholinesterase (the enzyme that breaks down acetylcholine) at parasympathetic nerve terminals supplying nasal mucosal vessels, shifting autonomic tone away from vasodilation.

ANSWER: A

Rationale:

Option A is correct. Cocaine is the only local anesthetic that produces clinically significant vasoconstriction, and it does so through inhibition of the presynaptic norepinephrine reuptake transporter (NET). By blocking NET, cocaine prevents the clearance of released norepinephrine from sympathetic synapses, allowing norepinephrine to accumulate and produce sustained stimulation of α-adrenergic receptors on vascular smooth muscle, resulting in vasoconstriction. This dual property — sodium channel blockade (anesthesia) plus norepinephrine reuptake inhibition (vasoconstriction) — makes cocaine uniquely suited for topical anesthesia of the nasal mucosa, where vasoconstriction is operationally desirable to reduce bleeding during nasal and sinus procedures. All other local anesthetics that are used with a vasoconstrictive effect require the addition of exogenous epinephrine as a separate adjuvant.

Option B: Option B is incorrect; cocaine does not directly activate α₁ receptors — its vasoconstrictive mechanism is indirect, through accumulation of endogenous norepinephrine by blocking its reuptake.
Option C: Option C is incorrect; cocaine does not inhibit calcium channels, and its lipid solubility is not the basis for its vasoconstrictive property.
Option D: Option D is incorrect; cocaine does not reverse the norepinephrine transporter to release stored neurotransmitter — that is the mechanism of amphetamine and related agents. Cocaine blocks the transporter in the reuptake direction.
Option E: Option E is incorrect; cocaine does not inhibit acetylcholinesterase, and parasympathetic innervation of nasal mucosal vessels is not the relevant pathway.

8. Among the physicochemical properties of local anesthetics, protein binding is the primary determinant of duration of action. Which of the following correctly explains why higher protein binding produces a longer block?

A) Higher protein binding increases the total volume of distribution (Vd) of the local anesthetic, meaning more drug is distributed into peripheral tissues including nerve tissue, producing a deeper and longer block through tissue depot formation.
B) Higher protein binding reduces renal clearance of the local anesthetic because protein-bound drug cannot be filtered at the glomerulus, prolonging the plasma half-life and therefore the duration of effect at the nerve.
C) Higher protein binding increases the lipid solubility of the local anesthetic, allowing it to penetrate the nerve sheath more deeply and reach a larger proportion of sodium channels within the axon.
D) Higher protein binding slows the onset of the nerve block because protein-bound drug cannot cross nerve membranes, requiring a longer equilibration time before the free fraction reaches the sodium channel.
E) Higher protein binding means the local anesthetic binds more avidly to protein components within the sodium channel itself, remaining associated with the channel for a longer period before dissociating — directly prolonging the duration of channel blockade and therefore the duration of the nerve block.

ANSWER: E

Rationale:

Option E is correct. The duration of local anesthetic action correlates with protein binding because local anesthetics bind to protein components of the Nav sodium channel (specifically the α-subunit inner vestibule). Agents with higher intrinsic protein binding affinity form more stable associations with the channel protein and dissociate more slowly, prolonging the duration of sodium channel block and therefore the clinical duration of the nerve block. Bupivacaine, with approximately 95% protein binding, has a clinical block duration of 4–12 hours or longer; lidocaine, with approximately 65% protein binding, has a block duration of 1–3 hours. This is why duration of action in local anesthetic pharmacology is remembered by the protein binding rank: bupivacaine > ropivacaine > mepivacaine > lidocaine > procaine.

Option A: Option A is incorrect; volume of distribution relates to drug distribution across body compartments, not to duration of nerve block — a high Vd would actually reduce plasma concentrations but does not directly prolong the nerve block.
Option B: Option B is incorrect; while renal clearance considerations are relevant to systemic kinetics, the duration of nerve block is determined by channel binding at the nerve, not by plasma half-life.
Option C: Option C is incorrect; protein binding and lipid solubility are independent physicochemical properties; high protein binding does not increase lipid solubility.
Option D: Option D is incorrect; protein binding does slow onset somewhat (because bound drug is unavailable to diffuse to the nerve), but this describes an onset effect, not the mechanism of prolonged duration, and the question asks about duration.

9. Ropivacaine was developed specifically to address the cardiac safety concerns associated with bupivacaine. Which of the following correctly identifies the structural basis for ropivacaine's improved cardiac safety profile?

A) Ropivacaine is a prodrug formulation of bupivacaine that is activated more slowly in cardiac tissue than in peripheral nerve tissue, producing equivalent anesthesia with a lower peak cardiac drug exposure.
B) Ropivacaine is the pure S(−)-enantiomer (single-stereoisomer form) of a pipecoloxylidide-class local anesthetic, whereas racemic bupivacaine contains both R(+)- and S(−)-enantiomers; the R(+)-enantiomer binds cardiac sodium channels with slower dissociation kinetics, and its absence in ropivacaine narrows the gap between the CNS-toxic dose and the cardiotoxic dose.
C) Ropivacaine contains a propyl side chain instead of bupivacaine's butyl side chain, which reduces its molecular weight sufficiently to prevent passage across cardiac myocyte membranes while preserving peripheral nerve penetration.
D) Ropivacaine is formulated at a lower concentration than bupivacaine (maximum 1% versus bupivacaine's maximum 0.75%), so the total milligram dose delivered is inherently lower, reducing absolute cardiac drug exposure regardless of kinetic differences.
E) Ropivacaine has a significantly higher pKa than bupivacaine, which means a smaller unionized fraction is available at physiologic pH to penetrate cardiac tissue — achieving cardiac protection through a kinetic barrier rather than a structural difference.

ANSWER: B

Rationale:

Option B is correct. Ropivacaine is the pure S(−)-enantiomer of a pipecoloxylidide-class local anesthetic. Racemic bupivacaine is a 50:50 mixture of R(+)- and S(−)-enantiomers. The R(+)-enantiomer of bupivacaine has significantly slower dissociation kinetics from the cardiac Nav1.5 sodium channel compared to the S(−)-enantiomer — meaning it is the R(+)-enantiomer that is primarily responsible for the "fast-in, slow-out" channel binding that underlies bupivacaine's cardiac danger. By using only the S(−)-enantiomer, ropivacaine retains effective peripheral nerve blockade while requiring approximately 40% higher plasma concentrations to produce equivalent cardiac toxicity compared to racemic bupivacaine. This provides a clinically meaningful — though not absolute — safety margin, particularly relevant for large-volume regional anesthesia techniques such as thoracic epidural analgesia and continuous peripheral nerve block infusions.

Option A: Option A is incorrect; ropivacaine is not a prodrug of bupivacaine — it is a distinct chemical entity in its own right.
Option C: Option C is incorrect; while ropivacaine does have a propyl side chain (versus bupivacaine's butyl chain), the reduced cardiac toxicity is explained by enantiomeric selectivity (absence of the R(+)-enantiomer), not by reduced molecular weight preventing myocyte penetration.
Option D: Option D is incorrect; the comparison is not based on concentration differences — the cardiac safety advantage is a pharmacodynamic property of the molecule, present regardless of dose.
Option E: Option E is incorrect; ropivacaine's pKa (8.1) is essentially the same as bupivacaine's (8.1), so there is no pKa-based kinetic barrier.

10. A patient is scheduled for outpatient shoulder surgery under interscalene nerve block (a regional anesthetic technique that blocks the brachial plexus at the neck to anesthetize the shoulder and upper arm). The anesthesiologist adds dexamethasone to extend the block into the first postoperative night. By approximately how many hours does dexamethasone extend the duration of a long-acting peripheral nerve block, and by what route is this effect best achieved?

A) Dexamethasone extends peripheral nerve block duration by approximately 1–2 hours when given perineurally (injected adjacent to the nerve), but this effect is not seen with intravenous administration because systemic glucocorticoids do not reach peripheral nerve tissue in sufficient concentrations.
B) Dexamethasone extends peripheral nerve block duration by approximately 12–16 hours but only when administered intraneurally (injected directly into the nerve fascicle), a route that is associated with nerve injury and therefore not used clinically.
C) Dexamethasone does not meaningfully extend peripheral nerve block duration; its clinical role in regional anesthesia is limited to reducing postoperative nausea and vomiting (PONV) through a central antiemetic mechanism.
D) Dexamethasone extends the duration of peripheral nerve blocks by approximately 6–8 hours, and this effect is achieved by either perineural administration (4–8 mg injected adjacent to the nerve) or systemic intravenous administration (8 mg IV) — with meta-analyses suggesting the two routes are approximately equivalent in their duration-extending effect.
E) Dexamethasone extends peripheral nerve block duration by approximately 6–8 hours, but only when given perineurally; intravenous dexamethasone has no effect on peripheral nerve block duration because the blood-nerve barrier (analogous to the blood-brain barrier) prevents systemic corticosteroids from reaching the nerve.

ANSWER: D

Rationale:

Option D is correct. Dexamethasone is one of the most evidence-supported adjuvants for extending peripheral nerve block duration, with randomized controlled trials and meta-analyses consistently demonstrating an extension of approximately 6–8 hours for both intermediate- and long-acting local anesthetics. Critically, this effect has been demonstrated with both perineural administration (4–8 mg dexamethasone injected adjacent to the nerve as part of the block) and systemic intravenous administration (8 mg IV). Meta-analyses suggest the two routes are approximately equivalent in their duration-extending effect — a finding with practical clinical implications. Because the IV and perineural routes produce similar benefit, many practitioners prefer systemic administration to avoid uncertain long-term local effects of corticosteroids on neural tissue with repeated perineural dosing. The clinical benefit is greatest in ambulatory surgery, where extending block analgesia into the first postoperative night significantly reduces opioid requirements and improves recovery.

Option A: Option A is incorrect; the effect is not limited to perineural administration — IV dexamethasone produces comparable block prolongation.
Option B: Option B is incorrect; intraneural injection (into the nerve itself) is specifically avoided due to nerve injury risk; the adjuvant is given perineurally (around the nerve), not intraneurally.
Option C: Option C is incorrect; while dexamethasone does have antiemetic properties, its block-prolonging effect is well established and clinically significant.
Option E: Option E is incorrect; systemic IV dexamethasone does extend block duration, demonstrating that the blood-nerve barrier is not an absolute barrier to this effect.

11. A patient with known pseudocholinesterase (butyrylcholinesterase) deficiency requires regional anesthesia. The anesthesiologist must choose a local anesthetic with this history in mind. Which of the following statements correctly describes the clinical implication of pseudocholinesterase deficiency for local anesthetic selection?

A) Pseudocholinesterase deficiency prolongs the duration of action of all local anesthetics equally, because pseudocholinesterase is the universal metabolic enzyme for the entire local anesthetic class regardless of chemical structure.
B) Pseudocholinesterase deficiency eliminates the safety advantage of bupivacaine over lidocaine, because bupivacaine's reduced cardiac toxicity depends on intact pseudocholinesterase activity to limit peak plasma concentrations.
C) Pseudocholinesterase deficiency selectively prolongs the plasma half-life of ester-class local anesthetics (such as chloroprocaine, procaine, and tetracaine) but has no clinically significant effect on amide-class agents (such as lidocaine, bupivacaine, and ropivacaine), which are metabolized by hepatic CYP enzymes.
D) Pseudocholinesterase deficiency is only clinically relevant for succinylcholine and has no meaningful effect on local anesthetic pharmacokinetics because local anesthetics are present in tissue, not plasma, during their primary period of action.
E) Pseudocholinesterase deficiency prolongs the duration of amide local anesthetics specifically, because amide agents undergo a secondary plasma hydrolysis step by pseudocholinesterase that supplements hepatic CYP metabolism under normal conditions.

ANSWER: C

Rationale:

Option C is correct. Pseudocholinesterase (also called butyrylcholinesterase) is the plasma enzyme responsible for hydrolyzing ester-class local anesthetics. In patients with pseudocholinesterase deficiency — whether inherited (dibucaine-resistant genotypes) or acquired (severe hepatic disease, pregnancy, malnutrition) — the hydrolysis of ester agents is substantially slowed. For chloroprocaine specifically, whose exceptional safety profile depends on a plasma half-life of under 60 seconds in normal individuals, pseudocholinesterase deficiency can extend the half-life to minutes or tens of minutes, eliminating the kinetic safety advantage that makes it suitable for high-dose obstetric use. Amide-class agents (lidocaine, bupivacaine, ropivacaine, mepivacaine, prilocaine) are metabolized by hepatic cytochrome P450 enzymes (CYP3A4, CYP1A2) and are completely unaffected by pseudocholinesterase activity or deficiency. Option E has the pharmacology inverted; it is ester agents, not amide agents, that are metabolized by pseudocholinesterase.

Option A: Option A is incorrect; pseudocholinesterase deficiency does not affect amide agents — the two drug classes use entirely different metabolic pathways.
Option B: Option B is incorrect; bupivacaine is an amide metabolized hepatically, and its cardiac safety profile is a pharmacodynamic property (enantiomeric channel binding kinetics), not dependent on pseudocholinesterase.
Option D: Option D is incorrect; pseudocholinesterase deficiency is clinically very relevant for ester local anesthetics — the claim that local anesthetics are only in tissue during their action period is incorrect, as absorbed drug enters the systemic circulation where plasma hydrolysis is the key safety mechanism for ester agents.

12. A medical student is studying the clinical applications of ester-class local anesthetics and asks about tetracaine. Which of the following correctly describes the clinical uses of tetracaine and the reason it is not used for peripheral nerve blocks?

A) Tetracaine is used for spinal anesthesia (intrathecal injection into the subarachnoid space) and for topical ophthalmic anesthesia; it is not used for peripheral nerve blocks because its high potency and narrow therapeutic window make the risk of systemic toxicity unacceptably high at the volumes required for peripheral block injection.
B) Tetracaine is used exclusively for topical mucosal anesthesia of the upper airway; its poor lipid solubility prevents effective penetration into peripheral nerve sheaths, limiting its utility to surface anesthesia only.
C) Tetracaine is an amide-class local anesthetic used for epidural anesthesia in obstetric practice; it is preferred over bupivacaine in labor analgesia because its metabolite does not cause methemoglobinemia in neonates.
D) Tetracaine is used for peripheral nerve blocks and epidural anesthesia in outpatient surgery; its ester-class structure and rapid plasma hydrolysis by pseudocholinesterase make it the safest option for ambulatory procedures.
E) Tetracaine has been withdrawn from clinical use in most countries due to a high rate of transient neurologic symptoms (TNS) following spinal administration, and is no longer available as a standard clinical agent.

ANSWER: A

Rationale:

Option A is correct. Tetracaine is an ester-class local anesthetic with high lipid solubility and high potency — approximately 10 times more potent than procaine on a milligram basis. Its established clinical roles are intrathecal (spinal) anesthesia, where doses of 5–20 mg provide reliable surgical anesthesia of varying level depending on baricity and patient positioning, and topical ophthalmic anesthesia, where 1–2 drops of 0.5% solution provide rapid corneal and conjunctival anesthesia for procedures such as tonometry, foreign body removal, and slit-lamp examination. Tetracaine is not used for peripheral nerve blocks or epidural anesthesia because its high potency means that the milligram doses required to block a large peripheral nerve or fill the epidural space would carry unacceptably high systemic toxicity risk — the therapeutic window between effective dose and toxic dose is too narrow at these volumes.

Option B: Option B is incorrect; tetracaine is not limited to upper airway mucosal use, and its lipid solubility is actually high (not poor), which contributes to its potency.
Option C: Option C is incorrect; tetracaine is an ester-class agent, not an amide, and it is not used in labor epidural analgesia.
Option D: Option D is incorrect; tetracaine is not used for peripheral nerve blocks or epidural anesthesia for the reasons stated above, and its rapid hydrolysis applies in the context of spinal use where the drug remains in the cerebrospinal fluid (CSF) rather than the systemic circulation.
Option E: Option E is incorrect; tetracaine remains available and in use for spinal anesthesia; transient neurologic symptoms (TNS) — a syndrome of transient buttock and leg pain after spinal anesthesia — are more prominently associated with hyperbaric lidocaine than with tetracaine.

13. When epinephrine is added to a lidocaine solution before peripheral nerve block injection, the maximum recommended dose of lidocaine increases from 4.5 mg/kg (maximum 300 mg) to 7 mg/kg (maximum 500 mg). What pharmacokinetic principle explains why the presence of epinephrine permits a higher total milligram dose of lidocaine to be safely administered?

A) Epinephrine activates hepatic β₂-adrenergic receptors, increasing hepatic blood flow and accelerating lidocaine's first-pass metabolism — reducing the effective systemic exposure for any given injected dose.
B) Epinephrine raises the pKa of the combined solution, shifting more lidocaine into the ionized form, which has reduced membrane permeability and therefore lower systemic absorption from the injection site.
C) Epinephrine chelates (chemically binds) lidocaine molecules in the injection solution, forming a complex with reduced aqueous solubility that slows the rate of dissolution and systemic uptake from tissue.
D) Epinephrine increases the protein binding of lidocaine in plasma, reducing the free (unbound) fraction at any given total plasma concentration and thereby raising the total plasma concentration required to produce CNS toxicity.
E) Epinephrine-induced vasoconstriction at the injection site slows the rate of systemic absorption of lidocaine into the bloodstream, keeping peak plasma concentrations (Cmax) below the threshold for CNS and cardiac toxicity even at a higher total injected dose — the dose is the same, but the rate of delivery to the systemic circulation is reduced.

ANSWER: E

Rationale:

Option E is correct. The maximum recommended dose of a local anesthetic is ultimately determined by the peak plasma concentration (Cmax) achieved after injection, and Cmax is determined not only by the total dose but critically by the rate of absorption from the injection site. Epinephrine-induced α₁-mediated vasoconstriction reduces local blood flow, slowing the rate of systemic absorption and lowering Cmax for any given total injected dose. Because the same total dose of lidocaine now produces a lower and more gradual rise in plasma concentration, a larger total dose can be administered while still keeping peak plasma levels below the threshold for CNS toxicity (approximately 5 μg/mL for lidocaine) and cardiac toxicity. This is a pharmacokinetic explanation: the total amount of drug is higher, but the peak systemic exposure is kept within safe bounds by the rate-limiting effect of vasoconstriction on absorption. This principle applies most strongly to lidocaine and mepivacaine (intrinsically vasodilatory agents where epinephrine substantially slows absorption) and less prominently to bupivacaine and ropivacaine (which already have slower absorption due to high lipid solubility and intrinsic vasoconstriction).

Option A: Option A is incorrect; epinephrine does not meaningfully increase hepatic blood flow at the doses used for local anesthetic mixtures, and lidocaine's hepatic metabolism is flow-dependent but not the reason the maximum dose increases.
Option B: Option B is incorrect; epinephrine does not raise the pKa of the solution, and pKa shift is not the mechanism.
Option C: Option C is incorrect; there is no chelation between epinephrine and lidocaine in solution.
Option D: Option D is incorrect; epinephrine does not alter lidocaine's plasma protein binding.

14. The 0.75% concentration of bupivacaine is contraindicated for obstetric epidural use. What event prompted the FDA to withdraw this concentration from obstetric epidural practice in 1984, and what does this restriction reflect about the pharmacology of concentrated bupivacaine?

A) The 0.75% concentration was withdrawn after a series of neonatal deaths caused by placental transfer of high-concentration bupivacaine producing fetal bradycardia and acidosis; the restriction reflects bupivacaine's high placental transfer ratio at concentrations above 0.5%.
B) The 0.75% concentration was withdrawn after reports of prolonged maternal hypotension lasting more than 30 minutes following epidural injection; the restriction reflects the vasodilatory properties of high-concentration bupivacaine at the thoracolumbar sympathetic outflow.
C) The 0.75% concentration was withdrawn after documentation of severe allergic reactions (anaphylaxis) in obstetric patients that were not seen with lower concentrations, reflecting a concentration-dependent antigen presentation unique to the 0.75% formulation.
D) The 0.75% concentration was withdrawn following reports of rapid cardiovascular collapse and death associated with accidental intravascular injection; the restriction reflects the principle that the highest concentration of a potent long-acting local anesthetic should not be used in settings where inadvertent IV injection is both likely and potentially catastrophic.
E) The 0.75% concentration was withdrawn after randomized trials demonstrated no analgesic advantage over 0.5% for surgical cesarean delivery, making the additional cardiac risk unjustifiable on a risk-benefit basis.

ANSWER: D

Rationale:

Option D is correct. In 1984, the FDA withdrew 0.75% bupivacaine from obstetric epidural use following multiple reports of sudden cardiovascular collapse and death in obstetric patients. The common thread was inadvertent intravascular injection of the concentrated solution — either through unrecognized intravascular catheter placement or through injection into an epidural vein — delivering a large bolus of highly concentrated bupivacaine directly into the systemic circulation. Given bupivacaine's "fast-in, slow-out" cardiac sodium channel binding kinetics, this produced refractory ventricular fibrillation and cardiac arrest. The obstetric setting is particularly high-risk for this complication: the epidural venous plexus is engorged during pregnancy, increasing the likelihood of intravascular catheter placement; laboring patients are often in lateral decubitus and hemodynamically stressed; and rapid resuscitation is complicated by the gravid uterus. The restriction embodies a broader principle of local anesthetic safety: the highest available concentration of a potent, long-acting agent should not be used routinely in settings where inadvertent intravascular injection is likely. Current obstetric epidural practice uses bupivacaine at 0.0625–0.25% for labor analgesia and 0.5% for surgical anesthesia when required.

Option A: Option A is incorrect; placental transfer of bupivacaine is actually relatively low due to high protein binding, and neonatal toxicity from epidural bupivacaine at standard concentrations is not the basis for the restriction.
Option B: Option B is incorrect; hypotension is a known complication of epidural anesthesia through sympathetic blockade, but prolonged hypotension is not the reason for the 0.75% withdrawal.
Option C: Option C is incorrect; bupivacaine allergy is exceedingly rare, and there is no concentration-dependent antigen presentation.
Option E: Option E is incorrect; the withdrawal was driven by patient safety reports, not by comparative efficacy trials.

15. Among the physicochemical properties of local anesthetics, lipid solubility is the primary determinant of potency. Which of the following correctly explains why higher lipid solubility produces a more potent local anesthetic?

A) Higher lipid solubility increases the aqueous solubility of the local anesthetic, allowing higher concentrations to be prepared in clinical solution and administered at greater milligram doses per injection volume.
B) Higher lipid solubility allows the local anesthetic to penetrate the lipid-rich myelin sheaths and axonal membranes more readily, achieving higher concentrations at the sodium channel binding site within the nerve for any given extracellular dose — requiring lower concentrations to produce equivalent conduction block.
C) Higher lipid solubility increases the ionized fraction of the local anesthetic at physiologic pH, and the ionized form binds with greater affinity to the charged inner vestibule of the sodium channel, directly increasing blocking potency.
D) Higher lipid solubility correlates with a lower molecular weight, allowing the drug molecule to physically fit within the sodium channel pore more precisely and produce a tighter, more complete channel block at lower concentrations.
E) Higher lipid solubility reduces the rate of local anesthetic metabolism by hepatic CYP enzymes because lipophilic molecules are sequestered in hepatic lipid stores rather than presented to metabolic enzymes, effectively prolonging both potency and duration simultaneously.

ANSWER: B

Rationale:

Option B is correct. The potency of a local anesthetic is expressed as the minimum concentration required to produce conduction block (Cm). Higher lipid solubility means the drug partitions more readily into the lipid-bilayer membranes of the myelin sheath and axonal membrane, achieving higher effective concentrations at the sodium channel binding site within the nerve for a given extracellular concentration. As a result, a lower total extracellular concentration is needed to produce the same degree of channel occupancy and conduction block — which is the definition of greater potency. Bupivacaine, with high lipid solubility, is clinically effective at concentrations of 0.0625–0.5%; lidocaine, with lower lipid solubility, requires concentrations of 1–2% for equivalent blocks at most sites. This is the same principle that governs the potency of inhalational anesthetic agents (Meyer-Overton rule) and reflects the lipid membrane as the pharmacologically relevant compartment.

Option A: Option A is incorrect; higher lipid solubility generally reduces aqueous solubility, not increases it — these properties are inversely related, and potency is not determined by the concentration of drug in aqueous solution.
Option C: Option C is incorrect; lipid solubility and ionization state (pKa) are independent properties, and the relationship described has the pharmacology inverted.
Option D: Option D is incorrect; lipid solubility and molecular weight are not inversely correlated in a clinically meaningful way, and potency is not determined by physical fit within the channel pore.
Option E: Option E is incorrect; while highly lipophilic drugs do have large volumes of distribution, hepatic metabolism of amide agents is flow-dependent and CYP enzyme–dependent, not limited by lipid sequestration in the liver.

16. A patient with severe hepatic cirrhosis (end-stage liver scarring with markedly reduced hepatic function) requires a peripheral nerve block. The anesthesiologist is concerned about local anesthetic toxicity from impaired drug clearance. Which of the following correctly identifies the metabolic pathway most relevant to this concern for amide-class local anesthetics?

A) Amide local anesthetics are primarily metabolized by plasma pseudocholinesterase, and hepatic cirrhosis is relevant only because severe hepatic disease reduces pseudocholinesterase synthesis — lowering the plasma enzyme level and slowing amide hydrolysis.
B) Amide local anesthetics undergo renal tubular secretion as the primary elimination route; hepatic cirrhosis impairs this indirectly through reduction in renal blood flow from portal hypertension, slowing urinary excretion of unchanged drug.
C) Amide local anesthetics are metabolized primarily by hepatic cytochrome P450 enzymes — principally CYP3A4 and CYP1A2 — and hepatic cirrhosis directly impairs this metabolic capacity, reducing clearance, prolonging plasma half-life, and increasing the risk of drug accumulation with repeated dosing.
D) Amide local anesthetics undergo spontaneous hydrolysis in plasma at physiologic pH independent of any enzyme; hepatic cirrhosis is relevant because reduced albumin synthesis increases the unbound fraction, not because metabolism is impaired.
E) Amide local anesthetics are metabolized by monoamine oxidase (MAO) enzymes in the liver; patients with hepatic cirrhosis have reduced MAO activity, and concurrent MAOI (monoamine oxidase inhibitor) therapy produces an additive impairment that dramatically elevates amide plasma concentrations.

ANSWER: C

Rationale:

Option C is correct. Amide-class local anesthetics — including lidocaine, bupivacaine, ropivacaine, mepivacaine, and prilocaine — are metabolized primarily by hepatic cytochrome P450 (CYP) enzymes, principally CYP3A4 and CYP1A2. In patients with significant hepatic dysfunction such as cirrhosis (Child-Pugh B or C), both CYP enzyme activity and hepatic blood flow are reduced, leading to decreased local anesthetic clearance, a prolonged plasma half-life, and increased risk of accumulation with repeated boluses or continuous infusion. The clinical implication is that maximum dose guidelines should be reduced by approximately 20–30% in patients with significant hepatic disease, and continuous infusion rates should be reduced and monitored more frequently. This is particularly important for bupivacaine and ropivacaine, which already have long half-lives (2–4 hours) in normal patients and can reach toxic steady-state concentrations in hepatically impaired patients on prolonged infusions.

Option A: Option A is incorrect; amide agents are not metabolized by pseudocholinesterase — that is the metabolic pathway for ester agents. While severe hepatic disease does reduce pseudocholinesterase synthesis (relevant for ester agents and succinylcholine), this has no bearing on amide metabolism.
Option B: Option B is incorrect; renal excretion of unchanged amide local anesthetic is minimal — hepatic metabolism is the primary route, not renal tubular secretion.
Option D: Option D is incorrect; amide agents do not undergo meaningful spontaneous plasma hydrolysis — the amide bond is chemically stable in aqueous solution at physiologic pH. Reduced albumin does affect protein binding and free fraction, but the primary concern in hepatic disease is metabolic clearance.
Option E: Option E is incorrect; amide local anesthetics are not metabolized by monoamine oxidase, and this is not a clinically relevant interaction pathway.

17. A patient scheduled for elective surgery reports that a first-degree relative experienced prolonged paralysis after receiving succinylcholine (a short-acting neuromuscular blocking agent that is also metabolized by pseudocholinesterase). A dibucaine number is ordered. Which of the following correctly interprets a dibucaine number result of 22 in this patient?

A) A dibucaine number of 22 indicates homozygous atypical (dibucaine-resistant) pseudocholinesterase genotype, in which the enzyme has markedly reduced activity; normal pseudocholinesterase produces a dibucaine number of 70–85, and a result of 22 means the patient's enzyme retains only approximately 22% of its activity when inhibited by dibucaine under the test conditions — indicating high risk for prolonged succinylcholine effect and substantially slowed ester local anesthetic hydrolysis.
B) A dibucaine number of 22 falls within the normal range (normal: 15–30); the family history of prolonged paralysis is therefore not explained by pseudocholinesterase abnormality and should prompt investigation of other causes such as phase II block from succinylcholine overdose.
C) A dibucaine number of 22 indicates heterozygous pseudocholinesterase deficiency; heterozygous patients have a dibucaine number of 20–30, mild enzyme impairment, and only a modest prolongation of succinylcholine effect of approximately 20–30 minutes rather than the hours seen with homozygous deficiency.
D) A dibucaine number of 22 indicates that the patient has acquired pseudocholinesterase deficiency from hepatic disease; acquired deficiency produces values in the 20–30 range, while inherited atypical genotypes produce values in the 40–60 range.
E) The dibucaine number measures the percentage of normal pseudocholinesterase activity present in the plasma sample; a result of 22 means 22% of the expected enzyme activity remains, consistent with severe acquired deficiency from malnutrition or organophosphate exposure, rather than a genetic variant.

ANSWER: A

Rationale:

Option A is correct. The dibucaine number is the standard clinical test for pseudocholinesterase (butyrylcholinesterase) genotype. It measures the percentage inhibition of the patient's pseudocholinesterase by dibucaine (a local anesthetic that preferentially inhibits normal enzyme) under standardized conditions. Normal enzyme (homozygous normal genotype) is strongly inhibited by dibucaine and produces a number of 70–85. The homozygous atypical (dibucaine-resistant) variant is resistant to dibucaine inhibition and produces a number of approximately 20–30, reflecting markedly reduced enzyme activity. Heterozygous carriers (one normal, one atypical allele) produce an intermediate number of approximately 40–60. A result of 22 is consistent with the homozygous atypical genotype, indicating that the patient is at high risk for prolonged succinylcholine-induced paralysis (potentially 4–8 hours or longer) and substantially prolonged hydrolysis of ester-class local anesthetics. This patient should receive a non-depolarizing neuromuscular blocker instead of succinylcholine, and ester local anesthetics should be used with caution at doses that depend on rapid plasma clearance for their safety profile. Option D has the genotype ranges inverted — acquired deficiency generally produces intermediate values (40–60 range), while the homozygous atypical genetic variant produces the lowest numbers (20–30).

Option B: Option B is incorrect; 22 is not within the normal range — normal is 70–85. A dibucaine number of 22 is markedly abnormal and consistent with the homozygous atypical genotype.
Option C: Option C is incorrect; heterozygous carriers produce a number of approximately 40–60, not 20–30; a result of 22 is lower than the heterozygous range and indicates homozygous atypical genotype.
Option E: Option E conflates the dibucaine number interpretation with a direct enzyme activity percentage; the dibucaine number is specifically a measure of inhibition by dibucaine under defined conditions, not a direct measurement of total enzyme activity remaining.

18. A patient is scheduled for endoscopic sinus surgery and the surgeon requests cocaine 4% topical solution for nasal mucosal anesthesia and hemostasis. The anesthesiologist reviews the medication list and discovers the patient takes phenelzine, a non-selective monoamine oxidase inhibitor (MAOI — a class of antidepressant that prevents the enzymatic breakdown of norepinephrine, dopamine, and serotonin). Why is cocaine contraindicated in this patient?

A) Cocaine is an ester-class local anesthetic whose plasma hydrolysis by pseudocholinesterase is inhibited by MAOIs; the combination prolongs cocaine's anesthetic duration to several hours, posing a risk of prolonged surgical field anesthesia and delayed recovery.
B) Cocaine undergoes hepatic metabolism by monoamine oxidase (MAO), and MAOI therapy prevents this metabolism entirely, producing a marked increase in cocaine plasma concentrations to potentially fatal levels even at topical doses.
C) MAOIs inhibit CYP3A4, the hepatic enzyme responsible for cocaine metabolism, reducing cocaine clearance by more than 90% and causing systemic accumulation to cardiotoxic concentrations.
D) Cocaine directly activates α₁-adrenergic receptors, and MAOIs upregulate α₁ receptor density through a compensatory mechanism; the combination of direct receptor activation and receptor upregulation produces an exaggerated vasopressor response.
E) Cocaine inhibits the presynaptic norepinephrine reuptake transporter, causing norepinephrine accumulation in sympathetic synapses; in a patient taking an MAOI, norepinephrine that cannot be cleared by reuptake also cannot be degraded by MAO, producing dangerous accumulation of norepinephrine with risk of hypertensive crisis, severe dysrhythmia, and hyperpyrexia.

ANSWER: E

Rationale:

Option E is correct. The cocaine-MAOI combination is one of the most clinically important drug interactions involving local anesthetics, and it explains why cocaine is formally contraindicated in patients currently taking or recently discontinuing an MAOI. Under normal physiologic conditions, norepinephrine released at sympathetic synapses is terminated by two parallel mechanisms: (1) reuptake via the norepinephrine transporter (NET) back into the presynaptic terminal, and (2) enzymatic degradation by MAO (monoamine oxidase) within the presynaptic terminal and in surrounding tissues. Cocaine blocks mechanism (1) by inhibiting NET; an MAOI such as phenelzine blocks mechanism (2) by irreversibly inhibiting MAO. When both mechanisms are simultaneously blocked, norepinephrine released by sympathetic activity accumulates to very high concentrations in synapses throughout the body, producing uncontrolled sympathetic stimulation — severe hypertension (potentially causing intracranial hemorrhage), tachycardia, ventricular dysrhythmias, hyperpyrexia (dangerous elevation of body temperature from excessive sympathetic activity), and in severe cases multi-organ failure and death. This reaction can occur even with topical nasal cocaine application because systemic absorption from nasal mucosa is substantial.

Option A: Option A is incorrect; cocaine is an ester metabolized by plasma pseudocholinesterase, and MAOIs do not inhibit this enzyme; block duration prolongation is not the mechanism of danger.
Option B: Option B is incorrect; cocaine is not metabolized by MAO — the interaction is not pharmacokinetic but pharmacodynamic, involving synergistic norepinephrine accumulation.
Option C: Option C is incorrect; MAOIs do not meaningfully inhibit CYP3A4, and cocaine's primary metabolism is plasma esterase hydrolysis, not hepatic CYP.
Option D: Option D is incorrect; MAOIs do not upregulate α₁ receptor density, and cocaine's mechanism is indirect (via NE reuptake inhibition), not direct α₁ receptor activation.

19. Clonidine is sometimes added to local anesthetic solutions for peripheral nerve blocks to extend their duration. What is the primary mechanism by which clonidine prolongs peripheral nerve blockade when administered perineurally (adjacent to the nerve)?

A) Clonidine acts as a weak sodium channel blocker in its own right; at perineural concentrations, it occupies a secondary binding site within Nav channels distinct from the local anesthetic site, producing additive channel blockade and extending total block duration.
B) Clonidine produces β₂-adrenergic–mediated vasodilation of arterioles at the injection site, paradoxically slowing local anesthetic clearance by reducing venous outflow from the tissue compartment surrounding the nerve.
C) Clonidine inhibits the reuptake of the local anesthetic at the nerve membrane by competitively blocking the sodium-potassium ATPase (Na⁺/K⁺ pump), maintaining the local anesthetic concentration at the channel binding site for a longer duration.
D) Clonidine activates α₂-adrenergic receptors on nociceptor (pain-sensing nerve fiber) membranes, which are coupled to Gi proteins (inhibitory G proteins); Gi activation reduces intracellular cAMP (cyclic adenosine monophosphate), hyperpolarizing the membrane and raising the action potential threshold — making the nerve less excitable and extending sensory and motor block.
E) Clonidine competitively inhibits the phospholipase A₂ enzyme that normally degrades local anesthetic molecules at the injection site, prolonging the pharmacologically active concentration of local anesthetic available to bind sodium channels.

ANSWER: D

Rationale:

Option D is correct. Clonidine is a selective α₂-adrenergic receptor agonist, and its mechanism of peripheral nerve block prolongation when given perineurally involves activation of α₂ receptors on nociceptor membranes. These receptors are coupled to Gi proteins (inhibitory G proteins), and their activation reduces adenylyl cyclase activity, lowering intracellular cAMP. The reduction in cAMP produces hyperpolarization of the nociceptor membrane — shifting the resting membrane potential away from the action potential threshold — and reduces the membrane excitability of nociceptive C-fibers and Aδ-fibers. This effect raises the threshold for action potential generation, prolonging both sensory and motor block components by approximately 2–4 hours when clonidine is added perineurally. At the neuraxial level (epidural or intrathecal), clonidine also provides analgesia through direct α₂ receptor activation in the dorsal horn of the spinal cord, suppressing substance P release and reducing ascending nociceptive transmission — a mechanism that is distinct from, and additive to, the peripheral nerve effect. The practical limitation of perineural clonidine is systemic absorption producing dose-dependent sedation and hypotension, which constrains the practical perineural dose to approximately 0.5–1 μg/kg.

Option A: Option A is incorrect; clonidine is not a sodium channel blocker and does not act at the local anesthetic binding site.
Option B: Option B is incorrect; clonidine activates α₂ receptors (and to a lesser extent α₁ receptors), producing vasoconstriction, not vasodilation; β₂ receptors mediate vasodilation, and clonidine has no significant β₂ activity.
Option C: Option C is incorrect; clonidine does not inhibit Na⁺/K⁺ ATPase, and this is not a mechanism of local anesthetic pharmacokinetics at the nerve.
Option E: Option E is incorrect; clonidine has no inhibitory effect on phospholipase A₂, and local anesthetic molecules are not degraded at the injection site by this enzyme.

20. EMLA cream is widely used to provide topical anesthesia of intact skin before venipuncture, IV cannulation, and superficial procedures in pediatric patients. Which of the following correctly describes the composition of EMLA cream and the physicochemical principle that enables it to penetrate intact skin?

A) EMLA cream contains lidocaine 4% as the sole active agent; it penetrates intact skin because lidocaine at this concentration exceeds the critical micelle concentration (CMC), forming lipid micelles that transport drug across the stratum corneum (the outermost, barrier layer of skin) by endocytosis.
B) EMLA cream is a eutectic mixture (a combination of two compounds in specific proportions that has a lower melting point than either component alone) of lidocaine 2.5% and prilocaine 2.5%; the eutectic formulation lowers the melting point of both agents below body temperature, allowing them to exist as an oil (free-base liquid form) that penetrates the lipid-rich stratum corneum to produce dermal analgesia.
C) EMLA cream contains benzocaine 20% in an oil-in-water emulsion vehicle; benzocaine's extremely low pKa means virtually all drug exists in the unionized free-base form at any pH, producing very rapid skin penetration without requiring a eutectic formulation.
D) EMLA cream contains tetracaine 1% and lidocaine 1% in a liposomal (lipid vesicle) encapsulation vehicle; the liposomes fuse with keratinocyte (skin cell) membranes in the stratum corneum, releasing the local anesthetics directly into the deeper dermal layers where nerve endings are located.
E) EMLA cream is a supersaturated solution of lidocaine 5% that slowly precipitates onto the skin surface; the crystalline precipitate acts as a sustained-release depot, providing prolonged slow absorption through the skin without requiring a eutectic mixture or special vehicle.

ANSWER: B

Rationale:

Option B is correct. EMLA is an acronym for Eutectic Mixture of Local Anesthetics, and the cream contains lidocaine 2.5% and prilocaine 2.5% in a specific eutectic formulation. A eutectic mixture is one in which two compounds, when combined in specific proportions, produce a mixture with a melting point lower than either component alone. For lidocaine and prilocaine, combining them at a 1:1 weight ratio lowers the melting point of the mixture to approximately 18°C — well below body temperature of 37°C. This means the mixture exists as an oil (liquid free-base form) at body temperature, rather than as solid crystalline particles that would not penetrate the skin barrier. The oil form is lipid-soluble and penetrates the lipid-rich stratum corneum to reach dermal nerve endings, producing clinically effective topical anesthesia after 45–60 minutes of application under an occlusive dressing. The methemoglobinemia risk from the prilocaine component is relevant when EMLA is applied over large surface areas, particularly in neonates or patients with G6PD deficiency.

Option A: Option A is incorrect; EMLA contains two agents (lidocaine and prilocaine), not lidocaine alone, and critical micelle concentration is not the mechanism of skin penetration.
Option C: Option C is incorrect; EMLA does not contain benzocaine, and benzocaine is associated with significant methemoglobinemia and allergic reactions; it is not a component of standard EMLA.
Option D: Option D is incorrect; EMLA does not contain tetracaine, and the formulation is not liposomal.
Option E: Option E is incorrect; EMLA is not a supersaturated solution, and crystalline precipitation does not occur — the eutectic principle specifically avoids this by producing a liquid oil at body temperature.

21. A surgeon requests a digital nerve block with lidocaine and epinephrine for a finger laceration repair. The anesthesiologist declines to add epinephrine to the block solution. Which of the following correctly identifies the reason epinephrine-containing local anesthetic solutions are contraindicated at end-arterial anatomic sites such as the digits?

A) Epinephrine is contraindicated for digital nerve blocks because the small volume of tissue in the digit allows epinephrine to be rapidly absorbed into the systemic circulation, producing exaggerated systemic adrenergic effects (hypertension, tachycardia) even at the concentrations used for regional anesthesia.
B) Epinephrine is contraindicated for digital blocks because it directly inhibits the local wound-healing response by suppressing fibroblast activity at the injury site, impairing tensile strength recovery after laceration repair.
C) End-arterial sites such as the digits, penis, pinna, and nasal tip are supplied by vessels with minimal or no collateral circulation; epinephrine-induced vasoconstriction at these sites can eliminate blood flow entirely, producing ischemia and potentially tissue necrosis if the vasospasm is prolonged or if baseline perfusion is already compromised.
D) Epinephrine is contraindicated for digital blocks because local alkaline tissue pH in the digit (maintained by high metabolic activity) shifts epinephrine to the ionized form, preventing the drug from crossing vascular smooth muscle membranes and producing paradoxical vasodilation instead of vasoconstriction.
E) Digital nerve blocks with epinephrine are contraindicated because the drug reaches the digital nerve directly and selectively blocks the sympathetic vasoconstrictor fibers traveling with the nerve, producing reflexive vasodilation in the finger and causing wound edge bleeding that cannot be controlled.

ANSWER: C

Rationale:

Option C is correct. The contraindication to epinephrine-containing solutions at end-arterial sites reflects the anatomy of the vascular supply at these locations. End-arterial sites — including the digits (fingers and toes), penis, pinna (outer ear), and nasal tip — are supplied by terminal arteries with no significant collateral circulation. Unlike most tissues, where vasoconstriction of one vessel can be compensated by increased flow through parallel collateral vessels, end-arterial structures have no collateral backup. Epinephrine-induced α₁-mediated vasoconstriction at these sites can reduce or eliminate perfusion entirely, and if the vasospasm is prolonged — or if the patient has underlying conditions compromising baseline perfusion such as peripheral vascular disease, Raynaud's phenomenon, or sickle cell disease — tissue ischemia and necrosis can result. It should be noted that multiple clinical studies have suggested that epinephrine in low concentrations (1:200,000 or 1:400,000) used in healthy patients for digital blocks carries a lower risk than historically taught, and some practitioners do use it selectively; however, the general clinical principle of avoiding epinephrine at end-arterial sites remains the standard recommendation and is the basis for the contraindication.

Option A: Option A is incorrect; systemic absorption from digital blocks is not greater than from other regional techniques, and systemic hemodynamic effects from epinephrine at 1:200,000 concentration are not the basis for the contraindication.
Option B: Option B is incorrect; epinephrine does not inhibit wound healing at standard local anesthetic concentrations.
Option D: Option D is incorrect; tissue pH does not selectively ionize epinephrine in this way, and the pharmacologic mechanism described is not a real phenomenon.
Option E: Option E is incorrect; digital nerve blocks do not selectively block sympathetic fibers, and reflexive vasodilation is not a clinically described phenomenon.

22. Mepivacaine is an amide local anesthetic with intermediate duration suitable for peripheral nerve blocks and epidural anesthesia in non-obstetric surgical patients. However, mepivacaine is specifically avoided for labor epidural analgesia. Which of the following correctly explains why mepivacaine is not used in the obstetric epidural setting?

A) Mepivacaine has a lower pKa than lidocaine, producing a larger unionized fraction that crosses the placenta more readily than other amide agents; the resulting fetal plasma concentrations approach toxic thresholds even at standard epidural doses used for labor analgesia.
B) Mepivacaine's intrinsic vasoconstrictive properties reduce uteroplacental blood flow when administered epidurally, producing fetal bradycardia and placental insufficiency during the critical period of labor.
C) Mepivacaine undergoes rapid conversion to a toxic metabolite in the acidic environment of fetal blood (which is slightly more acidic than maternal blood during labor), producing local anesthetic toxicity selectively in the fetus even when maternal plasma concentrations are within the safe range.
D) Mepivacaine causes dose-dependent uterine smooth muscle relaxation (tocolysis) when absorbed systemically from the epidural space, interfering with the normal uterine contractions necessary for labor progress and prolonging the second stage unacceptably.
E) Mepivacaine is eliminated poorly by neonatal liver enzymes, which are immature at birth; once mepivacaine crosses the placenta and accumulates in fetal tissues, the neonate cannot clear the drug effectively, leading to prolonged neonatal depression — in contrast to bupivacaine, whose high protein binding limits placental transfer, or lidocaine, which the neonate can metabolize more effectively.

ANSWER: E

Rationale:

Option E is correct. Mepivacaine is avoided in obstetric epidural analgesia primarily because of poor neonatal clearance. Unlike bupivacaine (which crosses the placenta minimally due to high protein binding, limiting fetal exposure) and lidocaine (which neonates can metabolize with reasonable efficiency), mepivacaine has pharmacokinetic properties that make it hazardous in the fetal-neonatal context. Mepivacaine crosses the placenta in meaningful quantities, and neonatal hepatic enzyme systems — which are immature at birth and have reduced CYP activity — cannot efficiently metabolize it. The result is prolonged neonatal plasma mepivacaine concentrations and dose-dependent neonatal central nervous system depression. This concern was identified in clinical reports and controlled studies from the 1960s and 1970s that demonstrated neonatal neurobehavioral depression lasting longer after mepivacaine epidural analgesia than after comparable bupivacaine or lidocaine exposure. As a result, mepivacaine was removed from routine obstetric epidural use despite its otherwise favorable properties (good onset, intermediate duration, low cardiac toxicity relative to bupivacaine). Bupivacaine at low concentrations (0.0625–0.125%) is the current standard for labor epidural analgesia.

Option A: Option A is incorrect; mepivacaine's pKa (7.6) is similar to lidocaine (7.9) and does not produce dramatically greater placental transfer than other agents.
Option B: Option B is incorrect; mepivacaine does not have clinically significant vasoconstrictive properties (that is a property specific to ropivacaine and cocaine), and uteroplacental vasospasm is not the mechanism.
Option C: Option C is incorrect; ion trapping in fetal blood (due to lower fetal pH) can increase fetal drug accumulation for all local anesthetics to a degree, but the specific concern with mepivacaine is neonatal clearance, not a toxic metabolite unique to acidic conditions.
Option D: Option D is incorrect; mepivacaine does not cause clinically relevant uterine relaxation.